Biomarkers and Beyond: Learning from Iressa – when and how to develop companion diagnostics
This article was originally published in Scrip
James Wade looks back over the path to market taken by one of AstraZeneca's oncology drugs and outlines some key lessons for pharmaceutical companies developing personalised cancer therapies. This article is part of Scrip's Biomarkers and Beyond analysis. For more articles, data and multimedia features exploring the role of biomarkers in the future of the pharmaceutical industry, visit scripintelligence.com/biomarkers.